List view / Grid view
Brazilian researchers have developed a new Zika virus vaccine that is safe and effective in mice – protecting against both brain inflammation and testicular damage while avoiding cross-reactions with dengue.
The 2025 chikungunya outbreak has surged from the Indian Ocean to Europe, prompting an urgent global research response. With no antivirals and limited vaccine access, laboratories and biotech firms are under pressure to deliver solutions fast.
Scientists have discovered that infections like COVID-19 and flu can “wake up” dormant breast cancer cells – triggering new tumour growth in the lungs.
Scientists at The Pirbright Institute have developed and successfully tested three experimental vaccines to protect pigs against the deadly Nipah virus - a first step to preventing transmission to humans.
Researchers at the University of North Carolina at Charlotte have used artificial intelligence to look at how the H5N1 bird flu virus is evolving to evade the immune system - insights that could make way for development of effective future therapies.
EPFL scientists have engineered virus-inspired DNA aptamers that bind infection targets with record selectivity. This innovation could change how we diagnose and treat infectious diseases.
Researchers in Norway have identified a promising oral drug combination that may stop the replication of enteroviruses, a group of viruses responsible for illnesses ranging from the common cold to type 1 diabetes.
The discovery from researchers at Johns Hopkins Medicine reveals how bacteria use the CRISPR-Cas system to store viral DNA, enhancing their immunity against future infections, and potentially paving the way for new phage-based therapies
New research reveals how B cells balance mutation and clonal expansion to refine their antibodies. This discovery could lead to more targeted and effective vaccine designs for various diseases.
Scientists at the University of Virginia (UVA) School of Medicine have uncovered a crucial mechanism behind the lingering effects of long COVID, revealing how severe COVID-19 infections impair immune cells’ ability to repair lung tissue.
The nasal spray reduced influenza virus levels by >99.99 percent, which could safeguard public health if validated in humans.
The mRNA vaccine candidate more effectively limited symptoms and disease duration in non-human primates.
The novel strategy demonstrates a strong immune response, both body-wide and specifically in the upper respiratory tract, in porcine models.
The new study demonstrated that a small molecule inhibitor, BLZ945, could be used as a potential therapeutic to achieve viral clearance.
KDR inhibitors could be very impactful for treatment of ATLL and HAM/TSP or prevent disease by lessening the viral load of HTLV-1.
